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With Atrial Fibrillation Treated With
Rivaroxaban or Warfarin
ROCKET AF TrialMatthew W. Sherwood, MD, MHS,* Christopher C. Nessel, MD,y Anne S. Hellkamp, MS,*
Kenneth W. Mahaffey, MD,z Jonathan P. Piccini, MD, MHS,* Eun-Young Suh, PHD,y Richard C. Becker, MD,*
Daniel E. Singer, MD,x Jonathan L. Halperin, MD,k Graeme J. Hankey, MD,{ Scott D. Berkowitz, MD,#
Keith A.A. Fox, MB, CHB,** Manesh R. Patel, MD*ABSTRACTFro
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hoBACKGROUND Gastrointestinal (GI) bleeding is a common complication of oral anticoagulation.
OBJECTIVES This study evaluated GI bleeding in patients who received at least 1 dose of the study drug in the on-
treatment arm of the ROCKET AF (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial.
METHODS The primary outcome was adjudicated GI bleeding reported from ﬁrst to last drug dose þ 2 days. Multi-
variable modeling was performed with pre-speciﬁed candidate predictors.
RESULTS Of 14,236 patients, 684 experienced GI bleeding during follow-up. These patients were older (median age 75
years vs. 73 years) and less often female. GI bleeding events occurred in the upper GI tract (48%), lower GI tract (23%),
and rectum (29%) without differences between treatment arms. There was a signiﬁcantly higher rate of major or
nonmajor clinical GI bleeding in rivaroxaban- versus warfarin-treated patients (3.61 events/100 patient-years vs. 2.60
events/100 patient-years; hazard ratio: 1.42; 95% conﬁdence interval: 1.22 to 1.66). Severe GI bleeding rates were similar
between treatment arms (0.47 events/100 patient-years vs. 0.41 events/100 patient-years; p ¼ 0.39; 0.01 events/100
patient-years vs. 0.04 events/100 patient-years; p ¼ 0.15, respectively), and fatal GI bleeding events were rare (0.01
events/100 patient-years vs. 0.04 events/100 patient-years; 1 fatal events vs. 5 fatal events total). Independent clinical
factors most strongly associated with GI bleeding were baseline anemia, history of GI bleeding, and long-term aspirin use.
CONCLUSIONS In the ROCKET AF trial, rivaroxaban increased GI bleeding compared with warfarin. The absolute
fatality rate from GI bleeding was low and similar in both treatment arms. Our results further illustrate the need for mini-
mizing modiﬁable risk factors for GI bleeding in patients on oral anticoagulation. (J Am Coll Cardiol 2015;66:2271–81)
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2272G astrointestinal (GI) bleeding is acommon complication of oral anti-coagulant (OAC) therapy that oc-
curs in 1% to 3% of patients on long-term
OAC therapy (1). Established risk factors for
GI bleeding in patients who receive vitamin K
antagonists (VKAs) include previous GI
bleeding, age, comorbid conditions, intensity
of anticoagulation therapy, and concomi-
tant medications (e.g., nonsteroidal anti-
inﬂammatory drugs [NSAIDs] and antiplatelet
agents) (2). However, the incidence and risk
factors for GI bleeding have not been well
studied in patients who take non-VKA
oral anticoagulants (NOACs). Management of
OAC in the setting of GI bleeding is controver-
sial, and the optimal strategy has not yet been
established (2,3).SEE PAGE 2282The ROCKET AF (Rivaroxaban Once-daily Oral
Direct Factor Xa Inhibition Compared with Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation) study was a randomized
controlled trial of rivaroxaban versus warfarin for the
prevention of stroke and systemic embolism in pa-
tients with nonvalvular atrial ﬁbrillation (AF) who
were at moderate to high risk for stroke (4). ROCKET
AF demonstrated that rivaroxaban was noninferior to
warfarin for the prevention of stroke and systemic
embolism (5), and rates of major and nonmajor clini-
cally relevant bleeding were similar between treat-
ment arms in the study. Patients randomized to
rivaroxaban had fewer intracranial hemorrhages
compared with warfarin, but they had signiﬁcantly
more GI bleeding (6). The objectives of this retro-
spective analysis were to investigate the incidence
and severity of GI bleeding, the factors associatedSt. Jude, and Tenax; has provided consulting or other services f
hringer Ingelheim, Bristol-Myers Squibb, Cubist, Eli Lilly, Elsevie
onic, Merck, Mt. Sinai, Myokardia, Omthera, Portola, Purdue Ph
d WebMD; and has equity in BioPrint Fitness. Dr. Piccini has
d Boston Scientiﬁc; and is a consultant for Johnson & Johnson an
nssen, Daiichi-Sankyo, and AstraZeneca; and a member of the safe
ant from Johnson & Johnson and Bristol-Myers Squibb; and is a co
, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Joh
and member of the advisory board for Bayer AG HealthCare,
rtho-McNeil-Janssen Pharmaceuticals, Pﬁzer, Sanoﬁ, AstraZene
Hankey has received honoraria from Bayer and Medscape (Heart
s a consultant and member of the advisory board for Sanoﬁ, As
esearch grant from Jansen, Bayer, and AstraZeneca; and has serve
enzyme, and Merck. All other authors have reported that they h
sclose. David Cannom, MD, served as Guest Editor for this paper
received May 3, 2015; revised manuscript received September 9with GI bleeding, and antithrombotic management of
GI bleeding in the ROCKET AF trial.
METHODS
The ROCKET AF trial design and primary results
have been previously published (4,5). Brieﬂy,
ROCKET AF was a double-blind, double-dummy, in-
ternational noninferiority trial that compared once-
daily rivaroxaban versus dose-adjusted warfarin for
the prevention of stroke or systemic embolism in
patients with nonvalvular AF. Patients had to have
previous stroke or transient ischemic attack or $2
risk factors for stroke. Patients with only 2 risk fac-
tors were capped at 10% of the overall trial popula-
tion, although the observed proportion of these
patients in the trial was 13%. The primary endpoint
was stroke or noncentral nervous system embolism.
Patients were monitored no less than once every
4 weeks.
STUDY POPULATION. We included all patients in the
on-treatment (or “safety”) population of the ROCKET
AF trial, which included those who were randomized
and received at least 1 dose of the study drug.
OUTCOMES. The primary safety outcomes for the
ROCKET AF trial were major and nonmajor clinically
relevant bleeding. In this study, we focused on
adjudicated GI bleeding reported during the safety
period (from ﬁrst drug dose to last dose þ 2 days). All
bleeds were adjudicated by a multispecialty clinical
events committee blinded to the patients’ treatment
assignments. GI bleeding events included upper GI,
lower GI, and rectal bleeding. GI bleeding was further
categorized by event classiﬁcation: the composite
principal safety endpoint (major or nonmajor clini-
cally relevant bleeding); major bleeding; major
bleeding with a hemoglobin drop of $2 g/dl; major
bleeding with transfusion; major bleeding withor the American College of Cardiology, AstraZeneca,
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2273transfusion of $4 U of whole blood or packed red
blood cells (PRBCs); major bleeding that was fatal;
and nonmajor clinically relevant bleeding.
In the outcomes analyses, only the ﬁrst GI bleed of
each type for each patient was considered. For sum-
maries of drug discontinuation and resumption, only
the last GI bleed of any kind for each patient was
considered. Permanent discontinuation of study drug
was deﬁned as the last dose received on the day of, or
1 or 2 days after, the patient’s last GI bleed. Patients
who died within this timeframe were not considered
discontinuations. All events that occurred while
patients received the study drug until 2 days after the
last dose of the study drug were included in the
analyses. Fatal bleeding events were those that
resulted in death within 30 days of a qualifying
bleeding event.
STATISTICAL METHODS. Multivariable modeling to
identify baseline characteristics associated with ma-
jor or nonmajor clinically relevant GI bleeding was
performed with candidate predictors, including age,
sex, diastolic blood pressure, estimated glomerular
ﬁltration rate (Cockcroft-Gault), previous GI bleed,
anemia, hypertension, diabetes, current or former
smoker, chronic obstructive pulmonary disease, sleep
apnea; previous long-term aspirin use, previous an-
tiplatelet use, and baseline use of NSAIDs, proton
pump inhibitors (PPIs), or H2 antagonists. These
variables were chosen based upon previous literature
that indicated them as likely factors associated with
GI bleeding (7). Continuous candidate predictors were
ﬁrst assessed for the linearity of their relationship
with GI bleeding, using restricted cubic splines, and
modiﬁcations (e.g., splines or truncations) made as
necessary.
Candidate predictors were then entered into a Cox
proportional hazards model, and forward stepwise
selection was used to select independent predictors.
Randomized treatment was forced into the model,
and interaction was tested to determine whether
predictors would differ depending on treatment as-
signment. Although the selection procedure in-
cluded only patients with complete data for all
candidate predictors, the ﬁnal model included all
patients with complete data for the selected pre-
dictors. International normalized ratio (INR) values
were entered as a time-dependent covariate by using,
at each event time, the mean of each patient’s INR
values from the previous 4 weeks. For event times
earlier than 4 weeks, the mean of available previous
INR values was used. INR values included all
values imputed by the Rosendaal method as part of the
time in therapeutic range (TTR) calculation. Theproportional hazards assumption was checked for all
ﬁnal predictors and found to have been met.
For assessing the association of randomized treat-
ment with GI bleeding outcomes, Cox proportional
hazards models were used that included randomized
treatment and all of the predictors identiﬁed previ-
ously. The proportional hazards assumption was
checked for randomized treatment in all models and
found to have been met. Due to differing length of
follow-up among patients, event rates are presented
as events per 100 patient-years.
Geographic variation was evaluated because of
previous data on differences in TTR. The cohort
was divided into North America (NA) and rest of
world (ROW), and GI bleeding event rates, adjusted
hazard ratios (HRs), and statistical interaction
were all calculated for these groups. The previously
described GI bleeding model was used, with region
replaced by the dichotomous NA and/or ROW vari-
able, and a term for the interaction between NA
and/or ROW and randomized treatment added.
Sensitivity analyses were also performed for all
bleeding events in these cohorts. All statistical anal-
yses of the aggregate, de-identiﬁed data were per-
formed by the Duke Clinical Research Institute using
SAS software (version 9.2, SAS Institute, Cary, North
Carolina).
RESULTS
POPULATION CHARACTERISTICS. Of the 14,236 pa-
tients enrolled in ROCKET AF, 684 (290 warfarin
[42%] and 394 [58%] rivaroxaban) had major and
nonmajor clinically relevant GI bleeds during follow-
up (Table 1). Compared with patients who did not
have GI bleeding, patients with GI bleeding were less
often female, slightly older (median age of 75 years),
and more likely to have used VKAs previously. There
was greater prevalence of renal insufﬁciency, dia-
betes, and hypertension in the GI bleeding popula-
tion, but these patients less often had a history of
thromboembolic events. Patients with GI bleeding in
the trial were more likely to have had a history of GI
bleeding, and there was an increased prevalence of
sleep apnea, chronic obstructive pulmonary disease,
and history of cigarette smoking in the GI bleeding
group compared with patients without GI bleeding.
The mean CHADS2, CHA2DS2-VASc, and HAS-BLED
scores were similar in patients with and without GI
bleeding. The pre-randomization use of aspirin or
NSAIDs was more common in patients with GI
bleeding. The use of PPIs and H2 antagonists was also
higher among patients with GI bleeding compared
with those without GI bleeding. For patients who
TABLE 1 Baseline Characteristics
All Safety
Patients
(N ¼ 14,236)
GI Bleed
(n ¼ 684)
No GI Bleed
(n ¼ 13,552)
Age, yrs 73 (65, 78) 75 (68, 79) 73 (65, 78)
Female 5,645 (40) 223 (33) 5,422 (40)
Type of AF
Persistent 11,525 (81) 570 (83) 10,955 (81)
Paroxysmal 2,511 (18) 106 (15) 2,405 (18)
New onset 200 (1) 8 (1) 192 (1)
CHADS2 score 3.5  0.9 3.4  0.9 3.5  0.9
1 3 (<1) 0 3 (<1)
2 1,855 (13) 101 (15) 1,754 (13)
3 6,203 (44) 293 (43) 5,910 (44)
4 4,085 (29) 190 (28) 3,895 (29)
5 1,809 (13) 89 (13) 1,720 (13)
6 281 (2) 11 (2) 270 (2)
CHA2DS2-VASc score 4.9  1.3 4.9  1.3 4.9  1.3
1 2 (<1) 0 2 (<1)
2 396 (3) 13 (2) 383 (3)
3 1,711 (12) 86 (13) 1,625 (12)
4 3,640 (26) 169 (25) 3,471 (26)
5 4,238 (30) 202 (30) 4,036 (30)
6 2,678 (19) 140 (20) 2,538 (19)
7 1,172 (8) 59 (9) 1,113 (8)
8 353 (2) 12 (2) 341 (3)
9 44 (<1) 3 (<1) 41 (<1)
HAS-BLED score 2.8  0.9 2.9  0.9 2.8  0.9
0 91 (1) 1 (<1) 90 (1)
1 979 (7) 30 (4) 949 (7)
2 4,258 (30) 180 (26) 4,078 (30)
$3 8,894 (62) 472 (69) 8,422 (62)
Presenting characteristics
BMI, kg/m2 28 (25, 32) 29 (26, 33) 28 (25, 32)
Systolic BP, mm Hg 130 (120, 140) 130 (120, 140) 130 (120, 140)
Diastolic BP, mm Hg 80 (70, 85) 78 (70, 83) 80 (70, 85)
Creatinine clearance,* ml/min 67 (52, 87) 65 (49, 84) 67 (52, 87)
Baseline comorbidities
Previous GI bleed 499 (4) 64 (9) 435 (3)
Previous stroke, TIA, systemic embolism 7,794 (55) 311 (45) 7,483 (55)
Congestive HF 8,894 (62) 417 (61) 8,477 (63)
Hypertension 12,887 (91) 634 (93) 12,253 (90)
Diabetes 5,683 (40) 298 (44) 5,385 (40)
Previous MI 2,460 (17) 143 (21) 2,317 (17)
PAD 836 (6) 57 (8) 779 (6)
COPD 1,493 (10) 112 (16) 1,381 (10)
Current or former smoker 4,781 (34) 311 (45) 4,470 (33)
Stopped >1 yr ago 3,589 (25) 244 (36) 3,345 (25)
Liver disease 746 (5) 42 (6) 704 (5)
Sleep apnea 645 (5) 61 (9) 584 (4)
Anemia 1,976 (14) 167 (25) 1,809 (14)
Continued on the next page
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2274experienced GI bleeding during trial follow-up, the
baseline clinical characteristics were similar between
treatment arms (Online Table 1).
GI bleeding events were distributed in the
following frequencies: 48% in the upper GI tract, 23%
in the lower GI tract, and 29% in rectal locations.These frequencies were similar between warfarin-
and rivaroxaban-treated patients (Table 2).
OUTCOMES. There were signiﬁcantly more GI
bleeding events in rivaroxaban-treated patients
versus warfarin-treated patients (3.61 events/100
patient-years vs. 2.60 events/100 patient-years; HR:
1.42; 95% conﬁdence interval [CI]: 1.22 to 1.66)
(Figure 1). When separated by clinical severity, there
were more major and nonmajor clinically relevant GI
bleeding events in rivaroxaban-treated patients
(Table 3). For the most severe bleeds, patients who
required$4 U of whole blood or PRBC transfusion, and
events that were fatal, there was a numerical balance
between treatment groups with no statistically sig-
niﬁcant difference detected. There was a very low
absolute rate of fatal GI bleeding, which occurred in
1 patient who received rivaroxaban and 5 patients
who received warfarin. The proportion of patients
who experienced fatal or severe GI bleeding that
required $4 U of RBCs was low and also similar be-
tween rivaroxaban- and warfarin-treated patients
(Central Illustration).
After multivariable adjustment for clinical charac-
teristics, patients who received rivaroxaban had
a signiﬁcantly higher hazard for both major and
nonmajor clinically relevant GI bleeding compared
with patients who received warfarin. This extended
to the subgroups of major bleeding, including GI
bleeds that involved a hemoglobin drop of $2 g/dl,
and GI bleeds that required transfusion, but this was
not signiﬁcant for fatal GI bleeds or in those who
required $4 U of RBC transfusion (Table 3).
STUDY DRUGANDANTIPLATELET THERAPYMANAGEMENT
IN THE SETTING OF GI BLEEDING. The decision to
re-start or permanently withdraw the study drug
after resolution of a bleeding event was left to the
discretion of the investigator according to local
practice. In the setting of GI bleeding, 34% of
patients remained on the study drug (21.1% of major,
47.9% of nonmajor clinically relevant bleeding),
whereas 27% permanently discontinued the study
drug either at the time of bleeding or 1 to 2 days
previously (Table 4). Patients with major GI bleeding
had higher rates of permanent discontinuation
compared with those with nonmajor clinically rele-
vant GI bleeding (27.6% vs. 10.7%). A total of 39% of
patients stopped the study drug at or near the time
of GI bleed and re-started the study drug afterward,
with a median duration of interruption of 9 days.
There was a similar frequency of study drug re-start
in patients with major versus nonmajor clinically
relevant GI bleeding (38.5% vs. 39.6%), although the
median duration of interruption was shorter in
TABLE 1 Continued
All Safety
Patients
(N ¼ 14,236)
GI Bleed
(n ¼ 684)
No GI Bleed
(n ¼ 13,552)
Medications
Previous VKA use 8,889 (62) 459 (67) 8,430 (62)
Previous long-term ASA use 5,194 (36) 291 (43) 4,903 (36)
NSAID use at baseline 507 (4) 35 (5) 472 (3)
PPI use at baseline 1,807 (13) 143 (21) 1,664 (12)
H2 antagonist use at baseline 311 (2) 23 (3) 288 (2)
Antiplatelet (other than ASA) at baseline 409 (3) 28 (4) 381 (3)
Randomized to rivaroxaban 7,111 (50) 394 (58) 6,717 (50)
Values are median (25th, 75th percentiles), n (%), or mean  SD. *Calculated using the Cockcroft-Gault
equation.
AF¼ atrial ﬁbrillation; ASA¼ aspirin; BMI¼ bodymass index; BP¼ blood pressure; CHA2DS2-VASc¼ congestive
heart failure, hypertension, age $75 years, diabetes mellitus, prior stroke or TIA or thromboembolism — vascular
disease, age 65–74 years, sex category; CHADS2¼ congestive heart failure, hypertension, age$75 years, diabetes
mellitus, prior stroke or TIA; COPD ¼ chronic obstructive pulmonary disorder; GI ¼ gastrointestinal; HAS-BLED ¼
hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly,
drugs or alcohol; HF ¼ heart failure; MI ¼ myocardial infarction; NSAID ¼ nonsteroidal anti-inﬂammatory drug;
PAD ¼ peripheral artery disease; PPI ¼ proton-pump inhibitor; TIA ¼ transient ischemic attack; VKA ¼ vitamin K
antagonist.
TABLE 2 Anatomical Locations of GI Bleeding Events
GI Bleed Location
All With
GI Bleeds
(n ¼ 684)
Rivaroxaban
(n ¼ 394)
Warfarin
(n ¼ 290)
Upper (hematemesis
or melena)
328 (48) 190 (48) 138 (47)
Lower 156 (23) 87 (22) 69 (24)
Rectal 200 (29) 117 (30) 83 (29)
Values are n (%).
GI ¼ gastrointestinal.
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2275patients with nonmajor clinically relevant GI
bleeding (16 vs. 7 days). Of patients who had a GI
bleed, 37.8% were on aspirin before their event,
whereas 15.5% were on another antiplatelet agent
before their event. Nearly one-half of these patients
remained on antiplatelet therapy during their GI
bleed, whereas the remaining patients stopped an-
tiplatelet agent use, and the majority of these pa-
tients stopped taking this therapy permanently.
Patterns of discontinuation of aspirin and anti-
platelet agents were similar for major and nonmajor
clinically relevant GI bleeding and were also similar
across treatment groups (Online Tables 2 and 3).
FACTORS ASSOCIATED WITH GI BLEEDING. As
shown in Table 5, multivariable modeling was used to
identify clinical factors associated with GI bleeding.
The factors most strongly associated with GI bleeding
were anemia at baseline, a history of GI bleeding,
long-term aspirin use, and rivaroxaban use (vs.
warfarin use). Other signiﬁcant clinical factors asso-
ciated with bleeding included increasing age, smok-
ing, diastolic blood pressure, history of PPI use,
history of obstructive sleep apnea, and decreasing
creatinine clearance. There was no interaction be-
tween predictors of GI bleeding and treatment
assignment (p ¼ 0.73 for interaction). Detailed infor-
mation on event rates for each of these subgroups can
be found in Online Table 4. Cubic spline plots,
generated to evaluate the effect of INR values on
GI bleeding, showed an inﬂection point at an INR of
2.0 (Figure 2). For every 1 U of increase in INR for
values <2.0, there was signiﬁcantly less hazard for
bleeding. For every 1 U of increase >2.0, there was
signiﬁcantly more hazard for major and nonmajor
clinically relevant GI bleeding.
GEOGRAPHIC VARIATION. When the study cohort
was divided into NA and ROW groups, there were
signiﬁcantly greater rates of TTR in NA patients
compared with those from the ROW (65.5 vs. 55.7;
p < 0.001). NA patients also had signiﬁcantly higher
rates of GI bleeding in both treatment arms compared
with the ROW patients (Table 6). After adjustment
for clinical risk factors, including concomitant
antiplatelet medications, patients in NA who received
rivaroxaban had a signiﬁcantly higher hazard
for GI bleeding than those on warfarin (p for
interaction ¼ 0.0069). There were also greater rates of
overall bleeding in NA versus ROW patients, but no
statistically signiﬁcant interaction was found be-
tween geographic location and treatment assignment
for overall bleeding (Online Table 5). The anatomic
location of GI bleeding was signiﬁcantly different
between NA and ROW patients, with a substantiallygreater proportion of GI bleeds in NA stemming from
a lower GI location (30% vs. 19%) and substantially
fewer GI bleeds proportionally from an upper GI
location (38% vs. 53%) compared with ROW patients
(Online Table 6). Use of antiplatelet agents was
similar among patients from NA compared with ROW,
both at baseline (37% vs. 40%) and during follow-up
(42% vs. 43%) (Online Table 7).
DISCUSSION
In a large, contemporary trial of moderate- to high-risk
patients with nonvalvular AF who received OAC,
rivaroxaban increased the rates of both major and
nonmajor clinically relevant GI bleeding compared
with warfarin (Central Illustration). Rates of the most
severe GI bleeding, including those that were fatal
and in patients who required $4-U RBC transfusion,
were very low and similar between rivaroxaban- and
warfarin-treated patients. Factors associated with GI
bleeding in patients on warfarin or rivaroxaban were
similar to previously established risk factors for GI
FIGURE 1 Kaplan-Meier Curve of Time to First Major GI Bleeding Event
by Treatment Arm
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Rivaroxaban-treated patients had a signiﬁcantly shorter time to their ﬁrst major gastro-
intestinal (GI) bleeding event compared with warfarin-treated patients during follow-up in
the ROCKET AF trial.
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2276bleeding. These results highlight a small but deﬁnite
risk for GI bleeding that might be attenuated by
minimizing concomitant risk factors.
RISK OF GI BLEEDING WITH NOAC. NOACs have
been associated with increased risk of GI bleeding
across several trials (6). This is in contrast to 2 recent
clinical registry analyses. Abraham et al. (8) and
Chang et al. (9), who both performed large U.S.
claims-based registry analyses and used propensity-
matched comparisons, showed that the risk of GI
bleeding was similar in patients who took dabigatran
or rivaroxaban compared with those who took
warfarin. When the results of all 4 clinical trials of
NOAC efﬁcacy in AF were pooled in a recent meta-
analysis from published reports and not patient-
level data (10), the NOACs, evaluated together,TABLE 3 Overall Rates of GI Bleeding by Treatment Arm
Outcomes
Rivaroxaban (n ¼ 7,111)
Events/100 Patient-Years
(Total Events)
Wa
Event
Major or NMCR bleeding 3.61 (394)
Major bleeding 2.00 (221)
Hemoglobin drop $2 g/dl 1.84 (204)
Transfusion 1.27 (141)
Transfusion $4 U 0.47 (52)
Fatal 0.01 (1)
NMCR 1.75 (193)
*Hazard ratios (HRs) and p values are from Cox proportional hazards models that inclu
bleeding (NMCR) GI bleeding (Table 5).
CI ¼ conﬁdence interval; other abbreviation as in Table 1.showed similar rates of major bleeding compared with
warfarin, but also had an overall slightly increased risk
for GI bleeding (HR: 1.25; 95% CI: 1.01 to 1.55; p¼ 0.04),
with signiﬁcant heterogeneity of effect (I2 > 70%).
The RE-LY (Randomized Evaluation of Long-Term
Anticoagulation Therapy) trial (11), which was a ran-
domized, open-label study of dabigatran versus dose-
adjusted warfarin for the prevention of stroke,
showed similar results (12). There was an excess of GI
bleeding (1.85% vs. 1.25%; p< 0.001) in patients on the
150 mg, twice-daily dose of dabigatran compared
with those on dose-adjusted warfarin. The ENGAGE
AF–TIMI 48 (Effective Anticoagulation with Factor Xa
Next Generation in Atrial Fibrillation—Thrombolysis in
Myocardial Infarction 48) trial also showed an
excess of GI bleeding (1.51% vs. 1.23%; p ¼ 0.03) in
patients who received 60mg of edoxaban versus dose-
adjusted warfarin (13). Alternatively, the ARISTOTLE
(Apixaban for Reduction in Stroke and Other Throm-
boembolic Events in Atrial Fibrillation) trial showed
similar rates of GI bleeding (0.76% vs. 0.86%; p ¼ 0.37)
in apixaban- versus warfarin-treated patients (14).
Thus, apixaban seems to be unique among the
currently approved NOAC agents with regard to GI
bleeding events. This is consistent with the overall
safety proﬁle of apixaban seen in the ARISTOTLE trial,
because it exhibited a reduced risk for major and
nonmajor clinically relevant bleeding compared
with warfarin. Despite the increased risk of GI
bleeding with rivaroxaban in our study, there were
very few fatal events in either treatment arm. In the
RE-LY and ENGAGE AF–TIMI 48 trials, rates of fatal
bleeding were also signiﬁcantly lower with dabiga-
tran and edoxaban compared with warfarin, but
data on the severity of GI bleeding are not yet
available. Our study provides the ﬁrst in-depth
analysis of a NOAC across the GI bleeding risk
spectrum. It also provides evidence that there is an
increased risk of GI bleeding with rivaroxaban, butrfarin (n ¼ 7,125)
s 100/Patient-Years
(Total Events)
Rivaroxaban vs. Warfarin
Adjusted HR (95% CI)* p Value
2.60 (290) 1.42 (1.22–1.66) <0.0001
1.24 (140) 1.66 (1.34–2.05) <0.0001
1.11 (125) 1.69 (1.35–2.12) <0.0001
0.85 (96) 1.56 (1.20–2.02) 0.0010
0.41 (47) 1.19 (0.80–1.77) 0.39
0.04 (5) 0.21 (0.02–1.76) 0.15
1.39 (156) 1.28 (1.43–1.59) 0.023
de randomized treatment and all identiﬁed predictors of major or nonmajor clinical
CENTRAL ILLUSTRATION GI Bleeding in ROCKET AF Trial: Histogram of the Distribution of GI Bleeding Stratiﬁed
by Treatment Arm
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Rivaroxaban-treated patients had higher rates of major and minor gastrointestinal (GI) bleeding events compared with warfarin-treated
patients; however, rates of the most severe GI bleeding events, including those that required transfusion of packed red blood cells and those
that resulted in death, were comparable between treatment groups.
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2277similar, extremely low rates of fatal GI bleeding
with warfarin and rivaroxaban.
MECHANISM OF GI BLEEDING WITH NOAC. The
possible mechanisms by which rivaroxaban, dabiga-
tran, and edoxaban are associated with a greater risk
of GI bleeding are not well understood. Dabigatran
and the factor Xa inhibitors, to a lesser degree, all
have partial elimination through the gut and are
substrates of the P-glycoprotein transport system (15).
This system actively pumps drugs into the GI tract,
allowing for greater concentrations of the active
agent to remain in the gut. Dabigatran has limited
bioavailability (7.2%) and is directly activated in the GItract, which allows for prolonged exposure to an
active anticoagulant compound. It also has tartaric
acid in the compound, which is thought to contribute
to dyspepsia. In this scenario, surface lesions in the GI
tract, with prolonged exposure to an active anticoag-
ulant compound, may be more likely to bleed. In
comparison, warfarin has extremely high bioavail-
ability and is absorbed fully from the gut, because
the unabsorbed form of warfarin is inactive (16).
Although this may explain the differential GI
bleeding risk seen with dabigatran compared with
warfarin, it does not explain the differential GI
bleeding risk seen between the factor Xa agents.
TABLE 5 Predictors
Anemia at baseline
Previous GI bleed
Long-term ASA use at
Rivaroxaban vs. warfar
Age (for each 5-yr incr
Diastolic BP (for each 5
to <80 mm Hg)
Smoking history (curre
History of sleep apnea
PPI at baseline
Creatinine clearance (fo
decrease to <60 m
COPD
Male
Baseline antiplatelet (o
Abbreviations as in Tables
TABLE 4 Study Drug, Antiplatelet Therapy Use Relative to GI Bleed Events
Medical Therapy
All Patients
With GI Bleeds
(N ¼ 679)
Major Bleeding
(n ¼ 351)
NMCR Bleeding
(n ¼ 328)
Study drug
Remained on study drug at time of bleed 231 (34.0) 74 (21.1) 157 (47.9)
Stopped before or at time of bleed and resumed later 265 (39.0) 135 (38.5) 130 (39.6)
Permanently discontinued at time of bleed 132 (19.4) 97 (27.6) 35 (10.7)
Had permanently discontinued 1 or 2 days before bleed 51 (7.5) 45 (12.8) 6 (1.8)
Number of days to resumption of study drug from bleed 9 (4, 25) 16 (6, 30) 7 (3, 14)
ASA
Received at any time post-randomization and before bleed 257 (37.8) 147 (41.9) 110 (33.5)
Remained on ASA at time of bleed 153 (22.5) 88 (25.1) 65 (19.8)
Stopped before or at time of bleed 104 (15.3) 59 (16.8) 45 (13.7)
Resumed ASA after bleed (within 90 days) 6 (0.9) 5 (1.4) 1 (0.3)
Days to resumption of ASA from bleed 15 (13, 16) 14 (13, 16) 15
Antiplatelet agent (not including ASA)
Received at any time post-randomization and before bleed 105 (15.5) 57 (16.2) 48 (14.6)
Remained on antiplatelet at time of bleed 47 (6.9) 24 (6.8) 23 (7.0)
Stopped before or at time of bleed 58 (8.5) 33 (9.4) 25 (7.6)
Resumed antiplatelet after bleed (within 90 days) 4 (0.6) 4 (1.1) —
Days to resumption of antiplatelet from bleed 55 (26, 69) 55 (26, 69) —
Values are n (%) or median (25th, 75th percentiles).
Abbreviations as in Tables 1 and 2.
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bioavailability; therefore, the less active compound
is allowed to pass through the gut. The elevated GI
bleeding rates seen with rivaroxaban and edoxaban
may be due to differential dose and pharmacoki-
netics of these drugs compared with apixaban.
Further investigation is necessary to understand this
phenomenon.
RISK FACTOR MODIFICATION FOR GI BLEEDING. For
patients with AF, risk stratiﬁcation is a critical step inof GI Bleeding (Major or NMCR)
Wald
Chi-Square HR (95% CI) p Value
31.9 1.70 (1.41–2.04) <0.0001
30.2 2.11 (1.62–2.76) <0.0001
screening 23.5 1.47 (1.26–1.72) <0.0001
in 20.1 1.42 (1.22–1.66) <0.0001
ease) 18.2 1.11 (1.06–1.17) <0.0001
mm Hg decrease 13.8 1.10 (1.05–1.16) 0.0002
nt or former) 13.6 1.37 (1.16–1.62) 0.0002
11.6 1.60 (1.22–2.10) 0.0007
9.7 1.36 (1.12–1.65) 0.0018
r each 5-U
l/min)
6.0 1.06 (1.01–1.12) 0.015
5.8 1.30 (1.05–1.61) 0.016
4.4 1.21 (1.01–1.44) 0.037
ther than ASA) 4.3 1.50 (1.02–2.21) 0.039
1 and 3.management. Current guidelines emphasize the use
of thrombotic risk scores and shared decision making
with patients, carefully considering stroke and
bleeding risks (17). The use of bleeding risk scores has
also been recommended, but may not affect thera-
peutic choices in the same way. Bleeding risk scores
often reﬂect high thrombotic risk as well; thus,
correction of modiﬁable risk factors before OAC
would be a prudent strategy rather than withholding
OAC (7). In a recent analysis of net clinical beneﬁt in a
large national cohort, Olesen et al. (3) found that VKA
use alone was beneﬁcial, regardless of bleeding risk.
In our study, there was no observed difference in the
bleeding risk score (HAS-BLED) or thrombotic risk
score (CHADS2, CHA2DS2-VASc) for patients with
GI bleeding versus without GI bleeding. Several
independent factors for GI bleeding identiﬁed in
our study, particularly previous GI bleeding, age,
decreasing creatinine clearance, and anemia at base-
line, agree with previously validated score-based risk
factors for bleeding (18). Potentially modiﬁable risk
factors identiﬁed in our study included the concom-
itant use of aspirin and other antiplatelet agents,
which are known risk factors for GI bleeding. A recent
ORBIT-AF (Outcomes Registry for Better Informed
Treatment of Atrial Fibrillation) analysis showed that
aspirin: 1) is often used in patients on OAC who do not
have a clear indication for long-term antiplatelet
therapy; and 2) signiﬁcantly increases the risk for
bleeding events (19). In the aforementioned net
TABLE 6 Geographic Variation in GI Bleeding Rates and Treatment Effect
Geographic
Location Treatment
GI Bleeding
Events per 100
Patient-Years
(Total Events)
HR (95% CI)
Rivaroxaban vs.
Warfarin p Value
NA Rivaroxaban 7.13 (156) 1.89 (1.45–2.45) <0.001
Warfarin 3.83 (90)
Rest of world Rivaroxaban 2.73 (238) 1.21 (1.00–1.47) 0.047
Warfarin 2.27 (200)
Interaction NA 
rivaroxaban
— — — 0.0069
NA ¼ North America; other abbreviations as in Tables 1 and 3.
FIGURE 2 Predicted 1-Year Event Rate (With Point-Wise 95% CI) for the “Average” Patient
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On multivariable modeling, predicted 1-year GI bleeding event rates were lowest for patients with average international normalized
ratio (INR) values of 2.0, with incremental increased risk for each INR unit above and below 2.0. Average values for all other covariates
shown for the range of 1st to 99th percentiles of INR distribution. CI ¼ conﬁdence interval; GI ¼ gastrointestinal.
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2279clinical beneﬁt analysis, concomitant aspirin and VKA
use increased bleeding risk without substantially
decreasing the risk of stroke compared with VKA use
alone (3). Reducing exposure to modiﬁable risk fac-
tors such as concomitant medications is essential to
optimizing the risk and/or beneﬁt balance, and is
currently recommended by international AF practice
guidelines (20,21).
Another possible modiﬁable risk factor for patients
on VKA agents is the maintenance of INR value in the
therapeutic range. Our data indicate that INR values
both substantially below and above 2.0 contributed to
the risk of major and nonmajor clinically relevant GI
bleeding. Although it may be counterintuitive that
lower INR values would also increase GI bleeding risk,
we believe that this serves as a surrogate marker (like
TTR) of medication nonadherence or comorbid illness
that would increase bleeding risk. INR variability
has been studied by Razouki et al. (22), who found
that high INR variability (regardless of results above
or below our clinical thresholds) was indepen-
dently associated with both adverse thrombotic and
bleeding events. This was supported in a separate
study by Lind et al. (23), who also measured INR
variability and came to similar conclusions, that high
variability is independently associated with higher
rates of all-cause mortality, stroke, bleeding, and
hospitalization. Thus, it remains imperative for pa-
tients on VKAs to carefully monitor INR values to
reduce risk for both stroke and bleeding.The association of PPI use with GI bleeding is
likely confounded by indication. Patients with a
history of GI bleeding, or perhaps with GI pathology
and/or symptoms, are at a higher risk for GI
bleeding, but are often administered PPI therapy as
treatment. PPI use is more frequent in patients
who have had GI bleeding or are at risk, but PPIs
are unlikely to have a causal association with GI
bleeding. Our results indicate previously validated
GI bleeding risk factors may have utility in a
contemporary population of patients taking a NOAC.
There was no interaction between treatment
assignment and predictors of GI bleeding; thus, the
risk predictors found in our study would have
utility in both warfarin- and rivaroxaban-treated
patients. However, there are few treatment
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with AF and additional stroke risk factors,
anticoagulation with rivaroxaban is associated with a
higher rate of major or nonmajor clinically relevant GI
bleeding than warfarin, but the rates of the most se-
vere GI bleeding complications are similar with these
agents.
TRANSLATIONAL OUTLOOK: Further studies are
needed to establish the optimal stroke prevention
strategy for patients with AF who face a high risk of
bleeding complications during long-term
anticoagulation.
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2280strategy data that indicate what level of GI bleeding
risk would nullify the beneﬁts of OAC for stroke
prevention in appropriate patients with AF (3,7).
There are no data available for NOACs in this
challenging situation (24), but the rates of discon-
tinuation of OAC, even in the setting of nonmajor
clinically relevant bleeding, were high in our study.
The interplay of bleeding risk factors with throm-
botic risk factors creates a challenging situation
for clinicians. Further investigation is necessary to
provide adequate anticoagulation strategies for
complex patients with thrombotic risk and risk for
GI bleeding.
Geographic variation in GI bleeding rates and haz-
ards was seen in our study population, even after
multivariable adjustment for differences in clinical
risk factors and differential use of antiplatelet agents.
This is not easily explained, but there was more
overall bleeding seen in NA versus ROW patients. In
addition, the anatomic location of bleeding was more
often in the lower GI tract in NA than in the ROW. This
may be due to disparate practice patterns and more
aggressive screening for anemia and lower GI malig-
nancy in NA compared with other geographic regions,
which may partly explain the higher reported rates of
bleeding.
STUDY LIMITATIONS. First, this was a post-hoc, non-
randomized, subgroup analysis of the ROCKET AF
trial. As such, the study was not powered for com-
parison of clinical outcomes in the GI bleeding
population of the trial. Also, we had only limited
data on management of the GI bleeds. Finally,
inclusion and exclusion criteria for the ROCKET AF
trial created a select population of moderate- to
high-risk patients; thus, ﬁndings for GI bleeding risk
may not be generalizable to a broader population of
patients.CONCLUSIONS
In the ROCKET AF trial, both major and nonmajor
clinically relevant GI bleeding events were more
frequent in patients taking rivaroxaban compared
with warfarin. The most severe bleeding events, such
as those that required transfusion of $4 U of RBCs
or those that caused death were balanced between
treatment groups. The absolute fatality rate from GI
bleeding events was very low in both treatment arms.
Our results further highlight the importance of the
risk and beneﬁt consideration of OAC in patients at
risk for GI bleeding and illustrate the need for mini-
mizing modiﬁable risk factors for GI bleeds.
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